- USDA approves TruCan™ Ultra B (Oral), a ½ mL oral Bordetella vaccine for dogs
- First USDA-licensed low-volume oral Bordetella bronchiseptica vaccine
- Demonstrated 93% preventable fraction against Bordetella-associated cough
- Designed to improve patient comfort using PureFil™ Technology
- Commercial launch expected in Q1 2026
Elanco Animal Health Incorporated announced U.S. Department of Agriculture approval of TruCan™ Ultra B (Oral), an oral vaccine designed to protect dogs against Bordetella bronchiseptica, a leading cause of canine infectious respiratory disease complex (CIRDC), commonly known as kennel cough.
TruCan Ultra B (Oral) is the first USDA-licensed ½ mL oral Bordetella vaccine for dogs, delivering proven protection in a reduced-volume dose intended to enhance patient comfort. The vaccine is manufactured using Elanco’s PureFil™ Technology, which removes unwanted proteins and debris to help reduce adverse reactions.
Safety and efficacy were demonstrated through both field safety studies and controlled challenge studies, including a 93% preventable fraction against Bordetella-associated cough. Field studies included client-owned dogs ranging from four weeks to 15 years of age.
The approval expands Elanco’s Tru vaccine portfolio, which is the first vaccine line recommended by Fear Free®. TruCan Ultra B (Oral) is expected to be commercially available in the first quarter of 2026.
Information sourced from the company’s press release.
